Monday, 23 March 2015

Debt financing of breakthrough treatments

"Debt-financing schemes for breakthrough pharmaceutical products might offer a win-win-win for patients, payers, and manufacturers. Patients would obtain access to medicines; payers could ensure such access while remaining fiscally prudent. For pharmaceutical companies, entering into such a scheme would clearly be a better business and public relations strategy than fighting discounts and coverage denials."

Borrowing for the cure: Debt financing of breakthrough treatments
S Mattke, E Hoch
RAND Corporation
March 2015

Read more here.

No comments:

Post a Comment